XHC – iShares Global Healthcare Index ETF (CAD-Hedged)

🌱 XHC Key Performance Drivers

An ETF that targets equities in the global health care sector is influenced by a range of factors spanning macroeconomic, industry-specific, geopolitical, and innovation-driven dynamics. Here’s a breakdown of key factors affecting its performance:

1. Regulatory Environment

FDA and EMA approvals: Delays or rejections of drug or device approvals can impact stock prices.
Healthcare reform: Policies on drug pricing, insurance coverage, or government healthcare programs (e.g., Medicare, NHS) can significantly influence revenues.
Patent laws and IP protection, especially in emerging markets, affect long-term profitability.

2. Drug Pipelines and Innovation

Positive clinical trial results or new drug/device approvals often boost share prices.
Failures or adverse side effects in clinical trials can cause sharp declines.
Strong R&D spending and biotech innovation support long-term growth.

3. Demographic Trends

Aging populations in developed countries increase demand for pharmaceuticals, medical devices, and care services.
Growth of middle classes in emerging markets expands access to healthcare and drives global demand.

4. Macroeconomic Conditions

Health care is somewhat defensive, meaning it typically holds up better in recessions due to inelastic demand.
However, global recessions may still reduce elective procedures and hurt companies reliant on discretionary health services.

5. Currency Fluctuations

For a global ETF, performance is impacted by foreign exchange risk, especially if revenues are earned globally but reported in a base currency (e.g., USD).
A strong USD can reduce the value of foreign earnings.

6. Public Health Crises

Pandemics or epidemics can create both risks and opportunities:
- Risks to elective care providers and hospital systems.
- Opportunities for vaccine makers, diagnostics companies, and PPE manufacturers.

7. Valuation and Market Sentiment

The sector can experience rotation depending on risk appetite:
- Moves into health care when markets are risk-averse (defensive).
- Moves out when growth sectors (e.g., tech) are favored.
Biotech tends to be more volatile and speculative than large pharma or medtech.

8. Geopolitical and Trade Factors

Trade policies, sanctions, or geopolitical tensions (e.g., China-U.S. relations) can impact supply chains and global sales.
Health policy changes in key regions (e.g., Europe, U.S., China) can alter pricing and reimbursement frameworks.

9. M&A Activity

Mergers and acquisitions are common in this sector, especially among biotech and pharma firms.
M&A can create short-term volatility but also unlock long-term value and scale.

10. ESG and Ethical Issues

Investors increasingly consider ethical practices, drug pricing policies, and patient safety.
Scandals or unethical practices can lead to reputational damage and divestment.

🔍 XHC Risk Assessment

As of May 2025, XHC is rated as moderate risk level by its issuer BlackRock. This ETF has 14 years of history, which is above average, and $486M in net assets, which is below average, compared to all iShares ETF on the TSX.

It can be used strategically to gain targeted exposure to equities of issuers in the healthcare sector of the global economy, however may not be suitable for more risk-adverse investors and those with shorter investment horizons.

Investing in XHC offers exposure to large, established healthcare companies around the world, which can make it more stable than many other sectors. However, it still carries risks. Changes in government healthcare policies, drug pricing regulations, or patent expirations can impact profits. Global events, such as pandemics or supply chain disruptions, may also affect performance.

In addition, because it holds stocks from around the world, currency fluctuations can add uncertainty. Currency hedging in an ETF helps protect Canadian investors from exchange rate fluctuations, providing more stable returns that closely reflect the underlying index’s performance. This can reduce volatility and make returns more predictable. However, hedging comes with costs, which can lower long-term gains, and may not be perfectly effective in rapidly moving markets. In periods when the foreign currency strengthens, a hedged ETF may underperform its unhedged counterpart.

While healthcare is often considered a defensive sector, XHC is still an equity investment and can go down in value, especially in broad market downturns.

🧭 XHC Trend Analysis

As of May 2025, a linear regression model on 14 years of XHC timeseries data produces an r-squared of 0.96, indicating a strong upward growth trend in this ETF with 96% of its price variations explained simply by the passage of time. Keep in mind however, that past performance does not necessarily guarantee future trends will continue the same way.

📈 Key Drivers of XHC’s Growth Trend from Nov 2011 to July 2015

1. Defensive Sector Appeal Amid Economic Uncertainty

In the aftermath of the 2008 financial crisis, investors sought stability in sectors less sensitive to economic cycles. Healthcare, with its consistent demand, attracted significant investment. For instance, the Health Care Select Sector SPDR ETF (XLV) achieved a cumulative return of 41.4% in 2013 and 25.1% in 2014. (TickerFunds)

2. Demographic Trends: Aging Populations

The increasing proportion of elderly individuals in developed nations led to higher demand for medical services, pharmaceuticals, and long-term care, benefiting healthcare companies.

3. Healthcare Reform and Expanded Coverage

The implementation of the Affordable Care Act in the U.S. expanded insurance coverage to millions, increasing the customer base for healthcare providers and insurers. This policy shift was viewed positively by investors, as it promised higher revenues for healthcare companies.

4. Biotech Innovation and M&A Activity

Advancements in biotechnology, including the development of novel therapies and personalized medicine, spurred investor enthusiasm. Additionally, a wave of mergers and acquisitions in the sector signaled growth opportunities and consolidation benefits.

5. Global Health Initiatives and Investments

International efforts to improve healthcare access, particularly in emerging markets, led to increased funding and infrastructure development. These initiatives opened new markets for healthcare companies, contributing to their growth.

6. Technological Advancements in Healthcare

The adoption of electronic health records, telemedicine, and wearable health devices improved healthcare delivery and efficiency. These innovations attracted investments and were seen as future growth drivers for the sector. (Deloitte United States)

📉 Key Drivers of XHC’s Decline Trend from Aug 2015 to Nov 2016

1. Global Economic Turbulence

Chinese Market Volatility: In mid-2015, China’s stock market experienced significant turmoil, with the Shanghai Composite Index dropping 43% between June and August. This led to global investor concerns about China’s economic slowdown and its impact on global growth.
Oil Price Collapse: Between 2014 and early 2016, crude oil prices plummeted from over $100 per barrel to below $30, leading to market instability and affecting sectors tied to energy and commodities. (Wikipedia, Wikipedia)

2. Healthcare Sector Challenges

Drug Pricing Scrutiny: High-profile cases of significant drug price hikes drew public and political attention, leading to increased scrutiny of pharmaceutical companies and concerns about potential regulatory actions.
Biotech Volatility: Biotechnology stocks, which had seen substantial growth, faced corrections due to valuation concerns and the broader market sell-off.(Wikipedia)

3. Political and Regulatory Uncertainty

U.S. Presidential Election: The 2016 election introduced uncertainties regarding future healthcare policies, especially with discussions about repealing or modifying the Affordable Care Act.
Brexit Referendum: The UK’s decision to leave the European Union in June 2016 led to global market volatility, affecting investor confidence across sectors, including healthcare. (Wikipedia)

📈 Key Drivers of XHC’s Growth Trend from Dec 2016 to Feb 2020

1. Macroeconomic Stability and Market Confidence

During this period, the global economy experienced steady growth, low unemployment, and moderate inflation. These conditions fostered investor confidence, benefiting various sectors, including healthcare.

2. Demographic Trends and Rising Healthcare Demand

An aging population in developed countries led to increased demand for healthcare services, pharmaceuticals, and medical devices. This demographic shift supported sustained growth in the healthcare sector.

3. Advancements in Biotechnology and Pharmaceuticals

Significant innovations in biotechnology, such as the development of novel therapies and personalized medicine, attracted investor interest. The approval of new drugs and treatments contributed to the sector’s positive performance.(WSJ)

4. Mergers and Acquisitions (M&A) Activity

The healthcare sector witnessed substantial M&A activity, as companies sought to expand their portfolios and enhance competitiveness. These consolidations often led to increased efficiencies and market share, positively impacting stock prices.

5. Policy Environment and Regulatory Developments

While political discussions around healthcare reform, such as the potential repeal of the Affordable Care Act, introduced some uncertainty, the sector largely navigated these challenges without significant disruption. Investors remained optimistic about the sector’s long-term prospects.

6. Defensive Nature of Healthcare Investments

Healthcare is traditionally considered a defensive sector, meaning it tends to perform well even during economic downturns. This characteristic made healthcare stocks attractive to investors seeking stability amid market volatility.

📉 Key Drivers of XHC’s March 2020 Crash

The March 2020 COVID crash had a significant but somewhat less severe and more nuanced impact on ETFs that target equities in the global health care sector.

Initial Impact – March 2020 Crash:

Like nearly all equity ETFs, global healthcare ETFs dropped in value during the initial COVID-induced panic. Investors sold assets indiscriminately in a flight to cash and safety, despite the sector’s perceived defensive nature.

Sector-Specific Dynamics:

Pharmaceuticals and biotech: Some companies were viewed as potential winners (e.g., Moderna, Pfizer, Gilead) due to vaccine and treatment development.
Medical equipment and services: Saw disruptions from paused elective procedures and overwhelmed hospital systems.
Health insurers: Faced uncertainty about pandemic-related costs and claim surges.

📈 Key Drivers of XHC’s Growth Trend from Apr 2020 to Sep 2021

Following the initial crash, markets began a remarkable recovery, with healthcare equities playing a significant role in the rebound. Several factors contributed to this resurgence:

Massive Fiscal and Monetary Stimulus: Governments and central banks worldwide implemented unprecedented stimulus measures to support economies. In the United States, the Federal Reserve cut interest rates to near zero and launched extensive quantitative easing programs. Congress passed significant fiscal packages, including the CARES Act, injecting trillions into the economy .(Wikipedia)
Accelerated Vaccine Development: The healthcare sector was at the forefront of combating the pandemic, with companies rapidly developing vaccines and treatments. The success of mRNA vaccines and other therapeutic advancements boosted investor confidence in biotech and pharmaceutical firms.
Renewed Focus on Healthcare Infrastructure: The pandemic highlighted the importance of robust healthcare systems, leading to increased investments in healthcare infrastructure, telemedicine, and digital health solutions. This shift attracted capital to healthcare ETFs and related equities.
Defensive Nature of Healthcare Stocks: Historically, healthcare stocks are considered defensive investments, tending to perform well during economic downturns due to consistent demand for medical services and products. This characteristic made them attractive to investors seeking stability amid ongoing uncertainties.(Wikipedia)

📉 Key Drivers of XHC’s Decline Trend from Oct 2021 to Nov 2023

1. Inflationary Pressures and Interest Rate Hikes

The global economy faced a significant surge in inflation during this period, with rates reaching multi-decade highs. In response, central banks, notably the U.S. Federal Reserve, implemented aggressive interest rate increases to curb inflation. These actions led to higher borrowing costs and tightened financial conditions, impacting equity valuations across sectors, including healthcare. (Wikipedia)

2. Political and Regulatory Uncertainty

The political landscape introduced uncertainties affecting the healthcare sector. For instance, the appointment of industry skeptics to influential positions raised concerns about potential regulatory crackdowns on programs like Medicaid and the Affordable Care Act. Such uncertainties prompted investor caution, contributing to stock price volatility. (WSJ)

3. Post-Pandemic Healthcare Dynamics

The aftermath of the COVID-19 pandemic brought unexpected challenges for health insurers. Companies like UnitedHealth Group and CVS Health faced higher-than-anticipated healthcare costs, driven by increased spending on specialty drugs and the return of patients seeking deferred medical care. These factors strained earnings and pressured stock prices within the sector. (WSJ)

4. Global Economic Volatility

Broader economic challenges, including supply chain disruptions and geopolitical tensions, contributed to a volatile market environment. The healthcare sector, while traditionally viewed as defensive, was not immune to these macroeconomic pressures, leading to fluctuations in investor sentiment and stock performance.

📈 Key Drivers of XHC’s Growth Trend From Dec 2023 to Aug 2024

1. Investor Rotation into Defensive Sectors: Amid concerns over economic slowdowns and inflationary pressures, investors sought refuge in defensive sectors. Healthcare, known for its stability and consistent demand, became an attractive option. Big pharmaceutical companies like Amgen, Johnson & Johnson, and AbbVie saw solid gains, with the NYSE Arca Pharmaceutical Index up 10% year-to-date by February 2025. (WSJ)

2. Strong Performance of Pharmaceutical Stocks: Companies with robust pipelines and fewer near-term patent expirations, such as Gilead, Vertex, and Eli Lilly, led the sector’s rally. Their focus on innovative treatments and steady growth attracted investor interest. (WSJ)

3. Continued Demand for Healthcare Services: The aging global population and ongoing healthcare needs ensured sustained demand for medical services and products, supporting the sector’s growth.

📉 Key Drivers of XHC’s Decline Trend from Aug 2024 to May 2025

1. Regulatory and Political Uncertainty: The appointment of Robert F. Kennedy Jr., a known vaccine skeptic, as the U.S. Secretary of Health and Human Services raised concerns about potential policy shifts. This development led to a selloff in vaccine and pharmaceutical stocks, both in the U.S. and Europe. (BNN, BNN)

2. Expiration of Insurance Subsidies: Analysts warned that the potential expiration of enhanced insurance subsidies could reduce the number of insured patients, impacting hospital revenues and leading to stock downgrades for major hospital chains. (BNN)

3. Rising Medical Costs: Companies like UnitedHealth Group reported unexpected spikes in care usage, particularly among Medicare Advantage enrollees, leading to reduced earnings forecasts and significant stock declines. (AP News)

4. Trade Tensions and Tariffs: The introduction of sweeping tariffs by the U.S. in April 2025 led to a global stock market crash, with healthcare companies like GE Healthcare and Philips citing significant financial impacts due to increased costs of imported medical equipment. (Reuters)

Disclaimer

The content provided on this blog is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed herein are those of the author(s) and do not reflect the views of any affiliated organizations or institutions.

All investment strategies and investments involve risk of loss. Nothing in this blog should be construed as a recommendation, solicitation, or offer to buy or sell any securities or other financial instruments. You are solely responsible for your investment decisions and should seek the advice of a qualified financial advisor or other professional before making any financial decisions.

The information on this site is provided “as is” without any representations or warranties, express or implied. The author(s) make no representations or warranties in relation to the accuracy, completeness, timeliness, or reliability of any information on this site or found by following any link on this site.

Past performance is not indicative of future results. The author(s) may hold positions in or have other financial interests in securities discussed on this blog.

By using this blog, you agree not to hold the author(s) liable for any losses, damages, or expenses that may arise from reliance on the information provided.

ETF Foresight